© Springer International Publishing AG 2017 355
A. Covic et al. (eds.), Resistant Hypertension in Chronic Kidney Disease,
DOI 10.1007/978-3-319-56827-0
A
ACE/ARB inhibition, 225
Activated renin-angiotensin-aldosterone
system, 199
Adiponectin, 115
Adrenaline hypothesis, 92
Adrenal steroid hormones, 336
Adverse effects, 191
Afferent fibers, 309
Afferent renal nerve activity (ARNA), 94
African American Study of Kidney Disease
and Hypertension (AASK) study,
41, 45
Afro-American/Asian patients, 42
Aging, 183
Albumin/creatinine ratio (ACR), 145
Albuminuria, 33, 261
Aldosterone, 131
Aldosterone blockage
mineralocorticoid receptor antagonists,
222–223
spironolactone, 223
Aldosterone escape pathway, 98
Aldosterone homeostasis, 98
Aliskiren in the Evaluation of Proteinuria in
Diabetes (AVOID) trial, 293
ALLHAT study, 80
Alpha-adrenergic blockers, 295
Alpha-agonists, 295
Alpha-blockers, 299
Ambulatory arterial stiffness index (AASI), 143
Ambulatory blood pressure monitoring
(ABPM), 15, 39, 60, 80, 143, 145,
312, 344, 345
altered BP profiles, 42–45
altered circadian profile, 44, 45
BP measurements, 39
catheter-based radiofrequency, 52
diuretic therapy, 53
and HBPM, 41
masked hypertension, 39
neurohumoral activity, 52
nocturnal BP, 40
office blood pressure, 40
pseudoresistance, 46–48
resistant hypertension, 45–51
RH in CKD, 49–52
role, 345
WCH, 39
American Heart Association (AHA), 59, 69,
77, 234, 285, 344
American Heart Association Scientific
Statement, 73
American Society of Hypertension (ASH), 233
Amphetamines, 46
Analgesic nephropathy (AN), 20
Angiotensin converting enzyme (ACE), 152
Angiotensin converting enzyme inhibitors
(ACEi), 174
Angiotensin II type 2 receptor (AT2R),
97, 263
Angiotensin receptor blockers (ARBs), 26,
174, 240, 268
Angiotensin type 1 receptor (AT1R), 100
Angiotensin-converting enzyme inhibitors
(ACE-I), 97, 268
Antihypertensive agents, 334
Antihypertensive-based strategy, 266
Antihypertensive drug groups, 284–285
Antihypertensive drugs, 42, 45